Key Takeaways GSK gets FDA nod for Exdensur as an add-on maintenance treatment for severe eosinophilic asthma.Exdensur cut annualized asthma exacerbations versus placebo in phase III SWIFT-1 and SWIFT-2 studies.Exdensur is the first twice-yearly biologic for asthma, while its CRSwNP FDA decision remains pending.GSK plc (GSK) announced that the FDA has approved Exdensur (depemokimab-ulaa), an ultra-long-acting IL-5–targeting biologic, as an add-on maintenance treatment of severe asthma with an eosinophilic p ...